SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Nortran Pharmaceutical -NRT.V

No earlier versions found for this Subject.


Return to Nortran Pharmaceutical -NRT.V
 
Nortran is a developer of antiarrhythmic and pain blocking drug. After some delay, they are going for Phase 1 trail of their antiarrhythmic in Brazil hopefully next few weeks. This company obtained financing by selling 2.5 million special warrants @0.80 each. Last Friday closed was 0.80. This stock was in the range of 0.8 to 1.2 during the last few months. Other biotech company in VSE e.g.
IZP was trading at 1.5-1.9 level. This one may be underperform. Any good suggestion?

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News